|
|
|
|
|
|
|
|
|
|
Super Quote | Detail Quote | Interactive Chart | Transaction | Related News | Related Securities | Company Information | Dividend Records | Short Sell
02616 CSTONE PHARMA-B
Nominal 
1.960 0.000 (0.000%) | 2024/06 - Interim RMB(K¥) | %Chg (Compare to Interim) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | 2020/12 RMB(K¥) | |
| Turnover | 254,165 | -2.795% | 463,842 | 481,363 | 243,718 | 1,038,832 |
| Cost of Sales | (82,136) | -23.974% | (159,547) | (202,985) | (106,832) | (241,421) |
| Gross Profit | 172,029 | 12.117% | 304,295 | 278,378 | 136,886 | 797,411 |
| 2024/06 - Interim RMB(K¥) | %Chg (Compare to Interim) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | 2020/12 RMB(K¥) | ||
| Change in FV & Impairment on Inv. Prop. | -- | -- | -- | -- | -- | -- | |
| Change in FV & Impairment on Others | -- | -- | -- | -- | -- | -- | |
| Profit / (Loss) on Disposal | -- | -- | -- | -- | -- | -- | |
| Other Non-operating Items | -- | -- | -- | -- | -- | -- | |
| Share of Results of Asso. & JCEs | 0 | -- | 0 | 0 | 0 | 0 | |
| Profit / (Loss) before Taxation | 15,699 | -- | (367,234) | (902,678) | (1,920,100) | (1,220,999) | |
| Taxation | 0 | -- | 0 | 0 | 0 | 0 | |
| Profit / (Loss) from Discontinued Operations | -- | -- | -- | -- | -- | -- | |
| Non-controlling Interests | 0 | -- | 0 | 0 | 0 | 0 | |
| Others | -- | -- | -- | -- | -- | -- | |
| Profit / (Loss) Attributable to Shareholders | 15,699 | -- | (367,234) | (902,678) | (1,920,100) | (1,220,999) | |
| 2024/06 - Interim RMB(K¥) | %Chg (Compare to Interim) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | 2020/12 RMB(K¥) | |
| Net Finance Costs / (Income) | 910 | -- | (13,067) | (1,195) | (7,561) | (22,841) |
| Depreciation & Amortisation | 24,007 | -16.144% | 58,190 | 44,540 | 22,661 | 14,801 |
| Directors' Emoluments | 15,423 | -62.201% | 59,498 | 83,640 | 120,698 | 164,101 |
| 2024/06 - Interim | %Chg (Compare to Interim) | 2023/12 | 2022/12 | 2021/12 | 2020/12 | |
| Auditor's Opinion Status | N/A | -- | Unqualified | Unqualified | Unqualified | Unqualified |
Market Valuation Indicators
| 2024/06 - Interim | %Chg (Compare to Interim) | 2023/12 | 2022/12 | 2021/12 | 2020/12 | |
| EPS (cts) | 1.000 | -- | -29.000 | -77.000 | -165.000 | -117.000 |
| DPS (cts) | 0.000 | -- | 0.000 | 0.000 | 0.000 | 0.000 |
| Dividend Payout Ratio (%) | -- | -- | -- | -- | -- | -- |
| Cash flow per share ($) | -- | -- | (0.466) | (0.521) | (1.274) | (0.486) |
| NBV per share ($) | 0.364 | -- | 0.356 | 0.375 | 1.017 | 2.516 |
| Remarks: | Real time quote last updated: 11/11/2024 08:39 |
| Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service. | |
| Profit / (Loss) Attributable to Shareholders (¥) | RMB 15,699,000 |
| %Change | -- |
| EPS / (LPS) | RMB 0.010 |
| NBV Per Share (¥) | RMB 0.364 |